- Home
- USGOW vs OSRHW Comparison
USGOW vs OSRHW Comparison
Compare USGOW & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USGOW | OSRHW |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Canada | United States |
| Employees | 9 | 21 |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | USGOW | OSRHW |
|---|---|---|
| Price | $1.64 | $0.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 16.4K | N/A |
| Earning Date | 02-14-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | N/A |
| 52 Week High | $2.80 | N/A |
Technical Indicators
Market Signals| Indicator | USGOW | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 47.59 |
| Support Level | $1.10 | $0.06 |
| Resistance Level | $1.69 | $0.07 |
| Average True Range (ATR) | 0.91 | 0.01 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 10.00 | 45.93 |
Price Performance
Historical ComparisonAbout USGOW U.S. GoldMining Inc. Warrant
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About OSRHW OSR Holdings Inc. Warrant
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.